Green Product
Trial Size

XEDAR Antibody

CATALOG NUMBER: 3855

Clonality:
Polyclonal
Tested Applications:
ELISA, IHC-P, WB
Host Species:
Rabbit
Species Reactivity:
Human
Conjugate:
Unconjugated
Specifications
Host Species:
Rabbit
Species Reactivity:
Human
Immunogen:
XEDAR antibody was raised against recombinant human XEDAR.
Conjugate:
Unconjugated
Tested Applications:
ELISA, IHC-P, WB
Application Note:
XEDAR antibody can be used for the detection of XEDAR by Western blot at 0.5 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 10 μg/mL.
Antibody validated: Western Blot in human samples and Immunohistochemistry in human samples. All other applications and species not yet tested.
Positive Control 1:
Cat. No. 1210 - HEK293 Cell Lysate
Positive Control 2:
Cat. No. 1376 - Human Skin Tissue Lysate
Positive Control 3:
Cat. No. 12-701 - Human Skin Tissue Slide
Purification:
XEDAR Antibody is affinity chromatography purified via peptide column.
Clonality:
Polyclonal
Isotype:
IgG
Physical State:
Liquid
Buffer:
XEDAR Antibody is supplied in PBS containing ≤0.09% sodium azide.
Concentration:
1 mg/mL
Storage Conditions:
XEDAR antibody can be stored at 4°C up to one year. Antibodies should not be exposed to prolonged high temperatures.
Ncbi Official Symbol:
EDA2R
Additional Names:
XEDAR Antibody: XEDAR, EDAA2R, EDA-A2R, TNFRSF27, XEDAR, UNQ2448/PRO5727/PRO34080, Tumor necrosis factor receptor superfamily member 27, X-linked ectodysplasin-A2 receptor, EDA-A2 receptor
Protein Accession Number:
AAQ89953
Protein Gi Number:
37222208
Ncbi Gene Id Number:
60401
User Note:
Optimal dilutions for each application to be determined by the researcher.
Background:
XEDAR Antibody: X-linked ectodysplasin-A2 receptor (XEDAR) is a recently isolated member of the tumor necrosis factor receptor family that is highly expressed during embryonic development and binds to ectodysplatin-A2 (EDA-A2). Two predominantly expressed isoforms, XEDAR-s and XEDAR-L, differ by only a 21-amino region at the juxtamembrane region of the cytoplasmic domain. Neither isoform possesses a death domain and both have been shown to act mainly through TRAF3 and TRAF6 to activate the NF-κB and JNK pathways. Cells transfected with XEDAR and treated with EDA-A2 cause the assembly of a secondary complex containing FADD, caspase-8 and caspase-10, leading to the activation caspase-8 and caspase-3, and finally apoptosis. The EDA-A2-induced apoptosis is dependent on caspase-9 activation, as various pharmacological and genetic inhibitors of caspase-8 blocked apoptosis following EDA-A2 treatment.
Background Reference 1:
Yan M, Wang LC, Hymowitz SG, et al. Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors. Science 2000; 290:523-7.
Background Reference 2:
Sinha SK, Zachariah S, Quinones HI, et al. Role of TRAF3 and -6 in the activation of the NF-κB and JNK pathways by X-linked ectodermal dysplasia receptor. J. Biol. Chem. 2002; 277:44953-61.
Background Reference 3:
Sinha SK and Chaudhary PM. Induction of apoptosis by X-linked ectodermal dysplasia receptor via a caspase 8-dependent mechanism. J. Biol. Chem. 2004; 41873-81.

FOR RESEARCH USE ONLY

For additional information, visit ProSci’s Terms & Conditions Page.

Disclaimer:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.

CATALOG NUMBER:

3855

List Size:
0.02 mg, 0.1 mg

List Price:

Price range: $99.00 through $445.00

Shipping Info
Customize your order
Custom Antibody Services

New & Featured Products

CATALOG NUMBER: PM-7369-HRP

CATALOG NUMBER: PM-7369-biotin

CATALOG NUMBER: PM-7369